Expanding Hemoglobin Conjugates: Novel Applications and Use Cases

Publication ID: 24-11857605_0002_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Expanding Hemoglobin Conjugates: Novel Applications and Use Cases,” Published Technical Disclosure No. 24-11857605_0002_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857605_0002_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,605.

Summary of the Inventive Concept

The present inventive concept leverages the core technology of thiosuccinyl-crosslinked hemoglobin conjugates to address unmet needs in diverse industries, including athletic performance, environmental remediation, cancer diagnostics, agriculture, and industrial wastewater treatment.

Background and Problem Solved

The original patent disclosed thiosuccinyl-crosslinked hemoglobin conjugates for repeated doses or prolonged exposure in pharmaceutical applications. However, the full potential of this technology remains untapped in other fields. The present inventive concept addresses this limitation by exploring new applications and use cases that were not originally considered.

Detailed Description of the Inventive Concept

The newly generated claims introduce novel applications of thiosuccinyl-crosslinked hemoglobin conjugates. For instance, Claim 1 describes a system for improving athletic performance by administering the conjugate to enhance endurance. Claim 2 outlines a method for reducing environmental pollutants by using the conjugates to absorb and break down toxic chemicals. Similarly, Claims 3-5 detail the use of these conjugates in cancer diagnostics, agricultural yield enhancement, and industrial wastewater treatment, respectively. These new applications capitalize on the unique properties of thiosuccinyl-crosslinked hemoglobin conjugates, such as their ability to bind to specific targets and facilitate biochemical reactions.

Novelty and Inventive Step

The novelty of the present inventive concept lies in the unexpected application of thiosuccinyl-crosslinked hemoglobin conjugates to unrelated fields, thereby creating new opportunities for innovation and problem-solving. The inventive step resides in the identification of these new use cases and the development of corresponding systems and methods.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different polymer types, linker chemistries, or crosslinking moieties to tailor the conjugates for specific applications. Additionally, the conjugates could be modified to target specific cell types or tissues, further expanding their potential uses.

Potential Commercial Applications and Market

The present inventive concept has significant commercial potential across multiple industries, including sports medicine, environmental remediation, cancer diagnostics, agriculture, and industrial wastewater treatment. The market size for these applications is substantial, and the inventive concept offers a unique value proposition by leveraging the established technology of thiosuccinyl-crosslinked hemoglobin conjugates.

CPC Classifications

SectionClassGroup
A A61 A61K38/42
A A61 A61K47/542
A A61 A61K47/545
A A61 A61K47/60
A A61 A61P9/10

Field of Art

Biomedical engineering and pharmaceutical chemistry, specifically protein conjugation technologies, polymer chemistry, and biomolecular modification techniques. Expertise requires advanced degrees in chemistry, biochemistry, or bioengineering with specialized knowledge of protein modification strategies and polymer conjugation methods

Person of Ordinary Skill (PHOSITA) Profile

A skilled practitioner with advanced training in protein engineering, capable of understanding complex molecular modification techniques, familiar with polyethylene glycol conjugation strategies, and experienced in designing functional biomolecular systems with enhanced properties

Obviousness Rationale

The published technical disclosure represents predictable extensions of the source patent's core technology by applying known thiosuccinyl-crosslinked hemoglobin conjugate principles to novel application domains. A person having ordinary skill would recognize that the fundamental molecular engineering approach disclosed in US 11857605 could be readily adapted to diverse fields by leveraging the conjugate's inherent binding and transport capabilities. The variations represent systematic exploration of a well-characterized molecular platform using standard biotechnological design principles.

Obvious Combinations & Variations

Source Patent Element
Thiosuccinyl-crosslinked hemoglobin conjugates with polyethylene glycol modifications
PTD Variation
Athletic performance enhancement system using hemoglobin conjugates
Obviousness Reasoning
Predictable application of known molecular transport mechanism to improve physiological oxygen delivery and metabolic efficiency, representing a standard biotechnological design approach
Source Patent Element
Polymer-modified hemoglobin with specific binding capabilities
PTD Variation
Cancer diagnostic tool using selective cell binding properties
Obviousness Reasoning
Known protein engineering technique of targeting specific cellular receptors, utilizing inherent molecular recognition capabilities of modified hemoglobin conjugates
Source Patent Element
Crosslinked hemoglobin with tunable polymer interactions
PTD Variation
Environmental pollutant absorption and chemical breakdown method
Obviousness Reasoning
Logical extension of molecular binding properties to environmental remediation, representing a foreseeable application of protein conjugate technology
Source Patent Element
Polyethylene glycol conjugation strategies for biomolecular modification
PTD Variation
Agricultural nutrient uptake enhancement system
Obviousness Reasoning
Predictable use of molecular transport mechanisms to facilitate biochemical interactions in agricultural contexts, representing a standard biotechnological problem-solving approach
Source Patent Element
Thiosuccinyl crosslinking with polymer modifications
PTD Variation
Industrial wastewater heavy metal removal method
Obviousness Reasoning
Foreseeable application of protein conjugate binding capabilities to environmental remediation, utilizing known molecular interaction principles
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857605 and the published technical disclosure, a person having ordinary skill in the art would find the claimed variations obvious and anticipated, as the disclosed methods represent predictable extensions of known thiosuccinyl-crosslinked hemoglobin conjugate technologies through standard biotechnological design principles and systematic exploration of molecular platform capabilities.

Original Patent Information

Patent NumberUS 11,857,605
TitleThiosuccinyl-crosslinked hemoglobin conjugates and methods of use and preparation thereof
Assignee(s)Billion King International Limited